HSGX News and Press, Histogenics Corporation

BOSTON and JERUSALEM, Nov. 21, 2019 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX) today announced that it has established a U.S. Headquarters in the Boston area and has hired Jonathan Lieber as its U.S.-based CFO. Mr. Lieber will be responsible for all investor relations, finance and a...

Privately held Ocugen (OCGN) has completed its merger with Histogenics (NASDAQ: HSGX ). More news on: Histogenics Corporation, Healthcare stocks news, Read more ...

BOSTON, Sept. 26, 2019 (GLOBE NEWSWIRE) -- Histogenics Corporation (Nasdaq: HSGX) (the “Company” or “Histogenics”) today announced that all proposals related to its proposed merger with Ocugen, Inc. (“Ocugen”) were approved by Histogenics’ st...

BOSTON, Sept. 12, 2019 (GLOBE NEWSWIRE) -- Histogenics Corporation (Nasdaq: HSGX) (the “Company” or “Histogenics”) today announced that it convened and then adjourned, without conducting any business, its special meeting of stockholders (the “Special Meeti...

BOSTON, Sept. 11, 2019 (GLOBE NEWSWIRE) -- Histogenics Corporation (Nasdaq: HSGX) (the “Company” or “Histogenics”) today announced that it intends to convene and then adjourn, without conducting any business, its special meeting of stockholders (the “Speci...

CORAL GABLES, FL / ACCESSWIRE / June 11, 2019 / This month the American Society of Clinical Oncology held its annual meeting in Chicago, which brought about more attention to the healthcare sector and biotechstocks . The recent deal between Merck and Tilos Therapeutics has sparked increased...

NEW YORK, NY / ACCESSWIRE / April 30, 2019 / Traders News Source, a leading independent equity research and corporate access firm focused on small and mid-cap public companies is issuing a comprehensive report on Histogenics Corporation (NASDAQ: HSGX), a clinical-stage company, focuses on ...

Histogenics Corporation (NASDAQ: HSGX ) and privately held Ocugen have agreed to merge in an all-stock deal after which Ocugen shareholders will own ~90% of the combined company and Histogenics stockholders ~10%. The combined company will do business as Ocugen, Inc. More news on: Hi...

BOSTON, Mass. and MALVERN, Penn., April 08, 2019 (GLOBE NEWSWIRE) -- Histogenics Corporation (Nasdaq: HSGX) and Ocugen, Inc., a privately held clinical-stage biopharmaceutical company focused on discovering, developing and commercializing a pipeline of innovative therapies that address rare...

HENDERSON, NV / ACCESSWIRE / February 20, 2019 / Biotech may have had a hard 2018, but the sector is making up for lost time at the start of this year. This may be just getting started as many fund managers are underweight in the industry and may have to chase this run. One more under the ra...